Article
HCV Replicon Systems: Workhorses of Drug Discovery and Resistance.
Frontiers in cellular and infection microbiology - 1 Jan 2020
Khan Shaheen, Soni Shalini, Veerapu Naga Suresh
Abstract excerpt
The development of direct-acting antivirals (DAAs) has revolutionized the state-of-the art treatment of HCV infections, with sustained virologic response rates above 90%. However, viral variants harboring substitutions referred to as resistance-associated substitutions (RASs) may be present in baseline levels and confer resistance to DAAs, thereby posing a major challenge for HCV treatment. HCV replicons have...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.